Skip to main content

Complex Sepsis Presentations, SEP-1 Compliance, and Outcomes.

JAMA network open2025-03-19PubMed
Total: 73.0Innovation: 7Impact: 8Rigor: 7Citation: 8

Summary

In 590 ED sepsis patients, noncompliance with SEP-1 was associated with older age, higher comorbidity burden, septic shock, organ dysfunction, atypical presentations, and concurrent noninfectious illness. While SEP-1 compliance correlated with lower crude mortality, the association disappeared after adjusting for illness severity and clinical complexity.

Key Findings

  • SEP-1 noncompliance associated with older age, higher comorbidity (Elixhauser >20), septic shock, kidney dysfunction, thrombocytopenia, nonfebrile presentation, impaired mental status, and concurrent noninfectious illnesses.
  • SEP-1 compliance associated with lower crude hospital mortality (11.9% vs 16.1%), but no significant difference after adjusting sequentially for demographics/comorbidities, infection source, severity, and complexity (final AOR 1.08; 95% CI 0.61–1.91).
  • Clinical complexity factors were more prevalent in noncompliant cases, suggesting confounding of SEP-1–mortality associations in prior observational studies.

Clinical Implications

Hospitals should interpret SEP-1 metrics in context, incorporate complexity markers into quality dashboards, and prioritize tailored pathways for atypical or concurrent noninfectious presentations.

Why It Matters

By demonstrating that clinical complexity confounds the observed mortality benefit of SEP-1 compliance, this study informs quality measurement and policy debates on sepsis bundles.

Limitations

  • Retrospective design with potential misclassification and residual confounding; moderate sample size from academic centers may limit generalizability.
  • SEP-1 adjudication and complexity measures depend on documentation quality and abstraction accuracy.

Future Directions

Develop risk-adjusted sepsis quality metrics incorporating complexity markers; test tailored care pathways for atypical presentations in pragmatic trials.

Study Information

Study Type
Cohort
Research Domain
Prognosis
Evidence Level
III - Retrospective multicenter cohort with stepwise multivariable adjustment
Study Design
OTHER